Cilta-cel Remissions Extend to Five Years
In the initial 20-patient cohort A subgroup of Phase 2 CARTITUDE-2, ten patients remained alive and progression-free five years after one cilta-cel infusion and without maintenance therapy. At 60.7 months median follow-up, five-year overall…
